^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

    Excerpt:
    ...- EGFRALKROS1 wildtype or unknown,or patients with EGFRALKROS1 mutations but refuse to receive corresponding inhibitors' treatment...
    Trial ID:
    NCT03636685
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2022
    Title:

    EP08.02-033 - Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study

    Published date:
    07/12/2022
    Excerpt:
    In the phase II trial, Pts with non-squamous non-small cell lung cancer (NSCLC) aged 70 years or older who had not received systemic chemotherapy were included. Pts harboring EGFR or ALK mutations were enrolled after the failure of TKIs therapy….The median PFS was 4.8 months (95% CI: 2.6-8.4) and the median OS was not reached, The ORR was 6% (2/34), and the DCR was 85% (29/34).
    Trial ID:
    ALTER0303